Welcome to our dedicated page for Option Care Health SEC filings (Ticker: OPCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Option Care Health, Inc. (OPCH) SEC filings page brings together the company’s official regulatory disclosures, as filed with the U.S. Securities and Exchange Commission. These documents provide detailed insight into how the nation’s largest independent provider of home and alternate site infusion services reports its financial condition, capital structure, governance changes and material agreements.
Investors can use this page to access current and historical 10-K and 10-Q reports, which contain audited and interim financial statements, segment information, risk factor discussions and management’s analysis of the business. For Option Care Health, these filings complement its earnings press releases that discuss net revenue, net income, earnings per share and non-GAAP measures such as Adjusted EBITDA, Adjusted net income and Adjusted diluted EPS, and they provide the underlying GAAP detail and reconciliations referenced in those releases.
The page also tracks Form 8-K filings, which Option Care Health uses to report material events. Recent examples include 8-Ks furnishing quarterly earnings press releases under Item 2.02, an 8-K describing a Fourth Amendment to the company’s Amended and Restated First Lien Credit Agreement under Item 1.01 and Item 2.03, and an 8-K outlining a Chief Financial Officer transition and related compensatory arrangements under Item 5.02. These filings explain changes to term loans and revolving credit facilities, leadership appointments and transitions, and other significant corporate actions.
Users interested in executive and director information can review proxy materials and governance-related filings, which describe board composition, executive compensation structures and incentive plans referenced in 8-K disclosures. For those monitoring potential insider activity, Form 4 and related ownership reports, when filed, show transactions by directors, officers and significant shareholders in OPCH stock.
To make this information more accessible, this page pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points from lengthy filings. Instead of reading an entire credit agreement amendment or multi-hundred-page annual report, users can quickly see what changed in Option Care Health’s debt terms, how non-GAAP metrics reconcile to GAAP results, or what new risks and governance details have been disclosed, and then drill into the full documents as needed.
Option Care Health, Inc. Chief Growth Officer Christopher L. Grashoff reported mixed equity transactions. He received a grant of 12,678 shares of common stock at no cost as part of a restricted stock unit award. According to the footnote, one third of these units vest on each of the first three anniversaries of the grant date. Separately, 259 shares were disposed of at
Option Care Health, Inc. Chief Human Resources Officer Michael Bavaro reported two equity transactions. He acquired 9,579 shares of common stock as a restricted stock unit award at a stated price of $0.00 per share. These units vest in three equal annual installments beginning on the first anniversary of the grant date.
He also disposed of 551 shares of common stock at $35.24 per share in a tax-withholding transaction used to satisfy obligations associated with equity compensation. After these transactions, his directly held common stock balance reported in the filing increased compared with prior holdings.
Option Care Health Chief Accounting Officer reports equity grant and tax share withholding. Nicole Maggio received 4,226 shares of common stock on
On
Option Care Health, Inc. reported that Chief Executive Officer John Charles Rademacher acquired 78,876 shares of common stock through a grant of restricted stock units. The award was at a stated price of $0.00 per share and increases his directly held position to 831,057 shares. These restricted stock units vest in three equal annual installments on the first, second, and third anniversaries of the grant date.
Adewunmi Femi reported acquisition or exercise transactions in this Form 4 filing.
Option Care Health, Inc. Chief Medical Officer Femi Adewunmi received a grant of 9,579 shares of common stock as an equity award. After this award, total directly held shares are 28,337. The restricted stock units vest in three equal annual installments on each of the first, second, and third anniversaries of the grant date.
Sethna Meenal reported acquisition or exercise transactions in this Form 4 filing.
Option Care Health, Inc. Chief Financial Officer Meenal Sethna reported an equity award of 27,045 shares of common stock, received as a grant with no cash price per share. These restricted stock units vest in three equal annual installments, and her directly held common stock increased to 82,112 shares after the award.
Option Care Health, Inc. reported that General Counsel and Corporate Secretary Collin Smyser acquired 15,213 shares of common stock through an equity award coded as a grant or other acquisition. The award consists of restricted stock units that vest in three equal installments on each of the first, second, and third anniversaries of the grant date.
After this grant, Smyser directly owns 94,215 shares of common stock. In addition, 2,500 shares are held indirectly through a revocable trust, reflecting separate indirect ownership.
Option Care Health, Inc. disclosed that its board of directors has increased the authorization for its 2025 share repurchase program from $500 million to $1 billion, with no specified expiration date. The company may buy back stock through open market purchases, privately negotiated transactions, block trades, or accelerated and other structured repurchase programs, with volume and timing determined by management based on market, regulatory, and corporate factors.
The company also furnished a press release with preliminary financial results for the three and twelve months ended December 31, 2025 and preliminary expectations for full year 2026, and an investor presentation tied to its appearance at the 44th Annual J.P. Morgan Healthcare Conference.
Option Care Health (OPCH) reported an insider purchase by a director. On November 3, 2025, the reporting person bought 38,000 shares of common stock at a weighted average price of $25.984 per share, executed across multiple trades priced between $25.835 and $26.235.
Following this transaction, the director beneficially owned 413,390 shares, held directly. The filing notes the weighted average and offers to provide detailed trade-by-trade pricing upon request.
Option Care Health (OPCH) filed its Q3 2025 10‑Q, reporting solid growth with stable profitability. Net revenue rose to $1,435,016,000 from $1,278,546,000, up 12.2% year over year, driven by increased acute and chronic therapy volumes. Gross profit was $272,902,000 versus $256,749,000, while operating income held at $84,507,000. Net income was $51,816,000 compared with $53,856,000, and diluted EPS was $0.32 versus $0.31.
For the first nine months, revenue reached $4,184,073,000 and net income was $149,081,000. The company closed the Intramed Plus acquisition for $117,247,000 (net of cash), adding referral sources and trademarks and increasing goodwill. It refinanced its First Lien Term Loan, cutting the rate to Term SOFR plus 1.75% and extending maturity to September 22, 2032, and added $49,600,000 of incremental debt. Cash from operations was $222,556,000; cash ended at $309,822,000. OPCH repurchased 6,805,621 shares year‑to‑date for $212,500,000, with $287,500,000 remaining under its authorization. Shares outstanding were 160,108,000 as of September 30, 2025.